Characterisation of the postprandial pharmacokinetics of spermidine in humans. Randomised, placebo-controlled, single-centre study in healthy volunteers; two-arm cross-over design with washout phase

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00029397

Enrollment

Registered

2022-07-01

Start date

2022-02-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

Group 1: Spermidine 20 mg/d p.o. Group 2: placebo

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: a) women and men aged 18 - 45 years old b) sufficient knowledge of German to understand the study documents and the procedure

Exclusion criteria

Exclusion criteria: a) BMI 29.9 kg/m² b) acute illness c) history of food allergy (especially soy protein allergy) d) intake of medicines and food supplements during the period 48 h before the start of the study until the end of the study (exception: oral contraceptives) e) consumption of illegal substances f) pregnancy and breastfeeding g) shift work h) strict vegan diet

Design outcomes

Primary

Measure	Time frame
time-dependent concentration course of putrescine, spermidine and spermine in blood and saliva (quantified by LC-GC-MS)	—

Secondary

Measure	Time frame
metabolite spectrum in blood (quantified by NMR metabolomics)	—

Countries

Germany

Contacts

Public ContactMartin Smollich

Institut für Ernährungsmedizin, Universitätsklinikum Schleswig-Holstein

martin.smollich@uksh.de045131018401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026